120 related articles for article (PubMed ID: 37051990)
1. Comparison of the effects of perioperative and adjuvant chemotherapy on outcomes of operable gastric cancer: A retrospective cohort experience from a tertiary cancer center.
Ali J; Humayun N; Ikram S; Bakar MA; ; Sheikh RM
J Pak Med Assoc; 2023 Apr; 73(4):812-815. PubMed ID: 37051990
[TBL] [Abstract][Full Text] [Related]
2. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
3. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
Cunningham D; Allum WH; Stenning SP; Thompson JN; Van de Velde CJ; Nicolson M; Scarffe JH; Lofts FJ; Falk SJ; Iveson TJ; Smith DB; Langley RE; Verma M; Weeden S; Chua YJ; MAGIC Trial Participants
N Engl J Med; 2006 Jul; 355(1):11-20. PubMed ID: 16822992
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH;
Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
[TBL] [Abstract][Full Text] [Related]
6. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
7. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
8. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.
Jo JC; Baek JH; Koh SJ; Kim H; Min YJ; Lee BU; Kim BG; Jeong ID; Cho HR; Kim GY
Asia Pac J Clin Oncol; 2015 Dec; 11(4):282-7. PubMed ID: 25856172
[TBL] [Abstract][Full Text] [Related]
10. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
Kuhnle PJ; Israel KF; Menges M
Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
[TBL] [Abstract][Full Text] [Related]
11. Perioperative versus postoperative chemotherapy for gastric cancer: A propensity score matched analysis.
Kumar S; Seshadri RA; Trivadi SG; Dhanushkodi M; Ellusamy HR
Asia Pac J Clin Oncol; 2020 Oct; 16(5):e252-e256. PubMed ID: 32725778
[TBL] [Abstract][Full Text] [Related]
12. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
14. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
15. Radical D2 gastrectomy with adjuvant chemotherapy for stage IB/II/III distal gastric cancers in the era of perioperative chemotherapy: A propensity matched comparison.
Singh HK; Chaudhari V; Batra S; Ostwal V; Ramaswamy A; Mokal S; Shrikhande SV; Bhandare MS
Am J Surg; 2022 Jun; 223(6):1055-1062. PubMed ID: 34756584
[TBL] [Abstract][Full Text] [Related]
16. Short-term curative effect of S-1 plus oxaliplatin as perioperative chemotherapy for locally advanced gastric cancer: a prospective comparison study.
Zhao Q; Li Y; Huang J; Fan L; Tan B; Tian Y; Yang P; Jiao Z; Zhao X; Zhang Z; Wang D; Liu Y
Pharmazie; 2017 Apr; 72(4):236-240. PubMed ID: 29441995
[TBL] [Abstract][Full Text] [Related]
17. Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis.
Choi M; Ishizawa S; Kraemer D; Sasson A; Feinberg E
Eur J Surg Oncol; 2022 Feb; 48(2):403-410. PubMed ID: 34446344
[TBL] [Abstract][Full Text] [Related]
18. A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
Zheng S; Zhou Y; Sun Y; Wang Z; Lu Y
Cancer Chemother Pharmacol; 2019 Oct; 84(4):819-827. PubMed ID: 31388724
[TBL] [Abstract][Full Text] [Related]
19. Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer.
Jiang Y; Li T; Liang X; Hu Y; Huang L; Liao Z; Zhao L; Han Z; Zhu S; Wang M; Xu Y; Qi X; Liu H; Yang Y; Yu J; Liu W; Cai S; Li G
JAMA Surg; 2017 Jul; 152(7):e171087. PubMed ID: 28538950
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
